Taboola is an AI-powered discovery platform serving over 600 million daily active users and delivering more than 450 billion personalized recommendations every month across the open web. Our mission is to help people discover content, products, and experiences they’ll love — when they are most likely to engage.

At the core of Taboola's platform is a sophisticated machine learning recommendation engine that processes massive-scale data in real time. Every second, our AI analyzes hundreds of signals — including user behavior, content semantics, contextual information, and collaborative trends — to optimize the match between users and content. This system continuously learns and adapts, ensuring relevant and high-quality recommendations across websites, devices, and mobile applications.

Our platform powers discovery for the world’s top publishers and digital properties, such as Yahoo, CNBC, BBC, NBC News, Business Insider, and The Independent. Taboola also drives e-commerce recommendations, enabling over 1 million monthly transactions for major brands like Walmart, Macy’s, Skechers, and eBay.

Founded in 2006 and listed on NASDAQ (TBLA), Taboola is headquartered in New York City with a global footprint, including R&D in Tel Aviv, Los Angeles, Hungary, and Taipei. Our team of engineers, data scientists, and AI researchers tackle some of the most exciting challenges in real-time large-scale recommendation systems, AI-driven personalization, and online monetization.

Join us as we push the boundaries of AI at scale and shape the future of discovery on the open web.

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City in 1849 in New York. Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than US$1 billion in annual revenues. In 2020, 52% of the company's revenues came from the United States, 6% came from each of China and Japan, and 36% came from other countries.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Our belief—and the core of our strategy—is that innovative, highly differentiated medicines provide large clinical benefits in addressing serious diseases. And we believe these medicines not only help patients, but also help reduce the social and economic burden of disease in society. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

AI Fund is a startup studio building new AI companies from the ground up. Our companies bridge AI technology and applications, focusing on industries and problems that we believe move the world forward. Founded by Dr. Andrew Ng, our team merges a deep understanding of AI technology with a proven ability to start new ventures. AI Fund is uniquely positioned to build AI businesses that can make an immediate and decisive impact.